Skip to NavigationSkip to content

FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote

Published on 14/07/16 at 08:37am

Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their proposed biosimilar for Enbrel (etanercept) in a unanimous 20-0 vote.

This news comes shortly after the FDA also recommended Amgen’s biosimilar candidate for Humira (adalimumab), also by unanimous vote. While the US has lagged behind in terms of approving biosimilars, 2016 looks set to become the year when the US begins to try catch up on the progress made by biosimilars in Europe.

For Novartis, the FDA recommended their biosimilar version of Amgen’s blockbuster for all five indications of the originator product, including rheumatoid arthritis, plaque psoriasis, psoriatic psoriasis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis.

Mark McCamish, head of global biopharmaceuticals development at Sandoz, says: “We are encouraged by today’s favourable advisory committee recommendation for our proposed biosimilar etanercept. As a global market leader in biosimilars, we are pleased to move one step closer toward our goal of expanding patient access with our proposed biosimilar etanercept.”

If finally approved by the FDA, it may however be a challenge to get the biosimilar to market. AbbVie has already taken action to block Amgen’s Humira biosimilar making it to market, and Amgen will find itself on the other side of the battle against Novartis. It may look to follow the same strategy of claiming further patent protection in a variety of areas, to prevent biosimilar versions making it to market.

Sean Murray

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches